Expleo Solutions working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

74.43×	74.43×	84.00×	92.45×	68.07×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1,487.35×	1,487.35×	2,165.65×	3,351.20×	2,075.15×
−1,412.92×	−1,412.92×	−2,081.65×	−3,258.75×	−2,007.08×
1.95×	1.90×	2.45×	1.95×	2.29×
1.26×	1.26×	1.28×	1.29×	1.68×
0.96×	0.96×	1.74×	0.79×	0.17×
0.70×	0.70×	1.08×	0.48×	0.12×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

EXPLEOSOL₹817.25

Expleo Solutions Limited

· Technology

₹ CrorePeersDSSL DIGITIDE CEINSYS IZMO ORIENTTECH AURUM BCG GENESYSMcap ₹1,268 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Receivable Days (DSO)	68.07	92.45	84.00	74.43	74.43
Payable Days (DPO)	2,075.15	3,351.20	2,165.65	1,487.35	1,487.35
Cash Conversion Cycle (days)	-2,007.08	-3,258.75	-2,081.65	-1,412.92	-1,412.92
Working Capital Turnover	2.29	1.95	2.45	1.90	1.95
Asset Turnover	1.68	1.29	1.28	1.26	1.26
Cash Conversion (CFO/Net Income)	0.17	0.79	1.74	0.96	0.96
CFO/EBITDA	0.12	0.48	1.08	0.70	0.70

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.